Duality Biologics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Dizal 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Laekna 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Adagene 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

AbelZeta Pharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Nanjing IASO Biotherapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

I-Mab 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

A 2026 cervical cancer strategy report covering HPV epidemiology, PD-1 and VEGF biology, Phase 3 competition, recent transactions and R&D positioning.

A 2026 endometrial cancer strategy report covering epidemiology, MMR segmentation, PD-1 and HER2 biology, Phase 3 competition, deal signals and R&D positioning.

A 2026 HR-positive HER2-negative breast cancer strategy report covering epidemiology, ESR1 and CDK4/6 biology, Phase 3 competition, deal signals and portfolio positioning.

CStone Pharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Everest Medicines 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.